Resveratrol has antiinflammatory and antifibrotic effects in the peptidoglycan‐polysaccharide rat model of Crohn's disease
dc.contributor.author | Rahal, Kinan | en_US |
dc.contributor.author | Schmiedlin‐ren, Phyllissa | en_US |
dc.contributor.author | Adler, Jeremy | en_US |
dc.contributor.author | Dhanani, Muhammad | en_US |
dc.contributor.author | Sultani, Victoria | en_US |
dc.contributor.author | Rittershaus, Ahren C. | en_US |
dc.contributor.author | Reingold, Laura | en_US |
dc.contributor.author | Zhu, Ji | en_US |
dc.contributor.author | McKenna, Barbara J. | en_US |
dc.contributor.author | Christman, Gregory M. | en_US |
dc.contributor.author | Zimmermann, Ellen M. | en_US |
dc.date.accessioned | 2012-04-04T18:42:24Z | |
dc.date.available | 2013-06-11T19:15:41Z | en_US |
dc.date.issued | 2012-04 | en_US |
dc.identifier.citation | Rahal, Kinan; Schmiedlin‐ren, Phyllissa ; Adler, Jeremy; Dhanani, Muhammad; Sultani, Victoria; Rittershaus, Ahren C.; Reingold, Laura; Zhu, Ji; McKenna, Barbara J.; Christman, Gregory M.; Zimmermann, Ellen M. (2012). "Resveratrol has antiinflammatory and antifibrotic effects in the peptidoglycanâ polysaccharide rat model of Crohn's disease ." Inflammatory Bowel Diseases 18(4): 613-623. <http://hdl.handle.net/2027.42/90530> | en_US |
dc.identifier.issn | 1078-0998 | en_US |
dc.identifier.issn | 1536-4844 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/90530 | |
dc.description.abstract | Background: Resveratrol has antiinflammatory and antifibrotic effects. Resveratrol decreases proliferation and collagen synthesis by intestinal smooth muscle cells. We hypothesized that resveratrol would decrease inflammation and fibrosis in an animal model of Crohn's disease. Methods: Peptidoglycan‐polysaccharide (PG‐PS) or human serum albumin (HSA) was injected into the bowel wall of Lewis rats at laparotomy. Resveratrol or vehicle was administered daily by gavage 1–27 days postinjection. On day 28, gross abdominal and histologic findings were scored. Cecal collagen content was measured by colorimetric analysis of digital images of trichrome‐stained sections. Cecal levels of procollagen, cytokine, and growth factor mRNAs were determined. Results: PG‐PS‐injected rats (vehicle‐treated) developed more fibrosis than HSA‐injected rats by all measurements: gross abdominal score ( P < 0.001), cecal collagen content ( P = 0.04), and procollagen I and III mRNAs ( P ≤ 0.0007). PG‐PS‐injected rats treated with 40 mg/kg resveratrol showed a trend toward decreased gross abdominal score, inflammatory cytokine mRNAs, and procollagen mRNAs. PG‐PS‐injected rats treated with 100 mg/kg resveratrol had lower inflammatory cytokine mRNAs (IL‐1β [3.50 ± 1.08 vs. 10.79 ± 1.88, P = 0.005], IL‐6 [17.11 ± 9.22 vs. 45.64 ± 8.83, P = 0.03], tumor necrosis factor alpha (TNF‐α) [0.80 ± 0.14 vs. 1.89 ± 0.22, P = 0.002]), transforming growth factor beta 1 (TGF‐β1) mRNA (2.24 ± 0.37 vs. 4.06 ± 0.58, P = 0.01), and histologic fibrosis score (6.4 ± 1.1 vs. 9.8 ± 1.0; P = 0.035) than those treated with vehicle. There were trends toward decreased gross abdominal score and decreased cecal collagen content. Procollagen I, procollagen III, and IGF‐I mRNAs also trended downward. Conclusions: Resveratrol decreases inflammatory cytokines and TGF‐β1 in the PG‐PS model of Crohn's disease and demonstrates a promising trend in decreasing tissue fibrosis. These findings may have therapeutic applications in inflammatory bowel disease. (Inflamm Bowel Dis 2011;) | en_US |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Fibrosis | en_US |
dc.subject.other | Inflammation | en_US |
dc.subject.other | Stricture | en_US |
dc.subject.other | Inflammatory Bowel Disease | en_US |
dc.title | Resveratrol has antiinflammatory and antifibrotic effects in the peptidoglycan‐polysaccharide rat model of Crohn's disease | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Pediatrics, Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | University of Michigan, Department of Internal Medicine, Division of Gastroenterology, Room 6520 MSRB I/SPC 5682, 1150 W. Medical Center Dr., Ann Arbor, MI 48109 | en_US |
dc.contributor.affiliationum | Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Statistics, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Pathology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | Ohio State University College of Medicine, Columbus, Ohio | en_US |
dc.contributor.affiliationother | Department of Internal Medicine, Division of Gastroenterology, Texas A&M Health Science Center College of Medicine, Temple, Texas | en_US |
dc.identifier.pmid | 22431488 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/90530/1/21843_ftp.pdf | |
dc.identifier.doi | 10.1002/ibd.21843 | en_US |
dc.identifier.source | Inflammatory Bowel Diseases | en_US |
dc.identifier.citedreference | Crowell JA, Korytko PJ, Morrissey RL, et al. Resveratrol‐associated renal toxicity. Toxicol Sci. 2004; 82: 614 – 619. | en_US |
dc.identifier.citedreference | Lee E‐S, Shin M‐O, Yoon S, et al. Resveratrol inhibits dimethylnitrosamine‐induced hepatic fibrosis in rats. Arch Pharm Res. 2010; 33: 925 – 932. | en_US |
dc.identifier.citedreference | Hong S‐W, Jung KH, Zheng H‐M, et al. The protective effect of resveratrol on dimethylnitrosamine‐induced liver fibrosis in rats. Arch Pharm Res. 2010; 33: 601 – 609. | en_US |
dc.identifier.citedreference | Li J, Qu X, Ricardo SD, et al. Resveratrol inhibits renal fibrosis in the obstructed kidney. Am J Pathol. 2010; 177: 1065 – 1071. | en_US |
dc.identifier.citedreference | Sutra T, Oiry C, Azay‐Milhau J, et al. Preventive effects of nutritional doses of polyphenolic molecules on cardiac fibrosis associated with metabolic syndrome: involvement of osteopontin and oxidative stress. J Agric Food Chem. 2008; 56: 11683 – 11687. | en_US |
dc.identifier.citedreference | Jing Y‐H, Chen K‐H, Yang S‐H, et al. Resveratrol ameliorates vasculopathy in STZ‐induced diabetic rats: role of AGE‐RAGE signalling. Diabetes Metab Res Rev. 2010; 26: 212 – 222. | en_US |
dc.identifier.citedreference | Zou J, Huang Y, Cao K, et al. Effect of resveratrol on intimal hyperplasia after endothelial denudation in an experimental rabbit model. Life Sci. 2000; 68: 153 – 163. | en_US |
dc.identifier.citedreference | Garcia P, Schmiedlin‐Ren P, Mathias JS, et al. Resveratrol causes cell cycle arrest, decreased collagen synthesis, and apoptosis in rat intestinal smooth muscle cells. Am J Physiol Gastrointest Liver Physiol. (in press). | en_US |
dc.identifier.citedreference | Sartor RB, Cromartie WJ, Powell DW, et al. Granulomatous enterocolitis induced in rats by purified bacterial cell wall fragments. Gastroenterology. 1985; 89: 587 – 596. | en_US |
dc.identifier.citedreference | Zimmermann EM, Sartor RB, McCall RD, et al. Insulin‐like growth factor I and interleukin 1β messenger RNA in a rat model of granulomatous enterocolitis and hepatitis. Gastroenterology. 1993; 105: 399 – 409. | en_US |
dc.identifier.citedreference | Adler J, Swanson SD, Schmiedlin‐Ren P, et al. Magnetization transfer helps detect intestinal fibrosis in an animal model of Crohn disease. Radiology. 2011; 259: 127 – 135. | en_US |
dc.identifier.citedreference | International Commission on Illumination. Proceedings of the CIE Expert Symposium ′97 on Colour Standards for Image Technology. Vienna, Austria: Commission Internationale de l'éclairage, CIE Central Bureau, 1998. | en_US |
dc.identifier.citedreference | Schwartz MW, Cowan WB, Beatty JC. An experimental comparison of RGB, YIQ, LAB, HSV, and opponent color models. ACM Trans Graph. 1987; 6: 123 – 158. | en_US |
dc.identifier.citedreference | Burke JP, Muslow JJ, O'Keane C, et al. Fibrogenesis in Crohn's disease. Am J Gastroenterol. 2007; 102: 439 – 448. | en_US |
dc.identifier.citedreference | Shankar S, Gyanendra G, Srivastava RK. Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. Frontiers Biosci. 2007; 12: 4839 – 4854. | en_US |
dc.identifier.citedreference | Kolgazi M, Şener G, Çetinel Ş, et al. Resveratrol reduces renal and lung injury caused by sepsis in rats. J Surg Res. 2006; 134: 315 – 321. | en_US |
dc.identifier.citedreference | Isaacs KL, Sartor RB, Haskill S. Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology. 1992; 103: 1587 – 1595. | en_US |
dc.identifier.citedreference | Inohara N, Ogura Y, Fontalba A, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem. 2003; 278: 5509 – 5512. | en_US |
dc.identifier.citedreference | Hebbar V, Shen G, Hu R, et al. Toxicogenomics of resveratrol in rat liver. Life Sci. 2005; 76: 2299 – 2314. | en_US |
dc.identifier.citedreference | Zimmermann EM, Li L, Hou YT, et al. Insulin‐like growth factor I and insulin‐like growth factor binding protein 5 in Crohn's disease. Am J Physiol Gastrointest Liver Physiol. 2001; 280: G1022 – G1029. | en_US |
dc.identifier.citedreference | Pucilowska JB, McNaughton KK, Mohapatra NK, et al. IGF‐I and procollagen a1(I) are co‐expressed in a subset of mesenchymal cells in active Crohn's disease. Am J Physiol Gastrointest Liver Physiol. 2000; 279: G1307 – G1322. | en_US |
dc.identifier.citedreference | Yu H, Rohan T. Role of the insulin‐like growth factor family in cancer development and progression. J Natl Cancer Inst. 2000; 92: 1472 – 1489. | en_US |
dc.identifier.citedreference | Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin‐like growth factor‐I (IGF‐I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst. 2002; 94: 972 – 980. | en_US |
dc.identifier.citedreference | Patel KR, Brown VA, Jones DJL, et al. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res. 2010; 70: 7392 – 7399. | en_US |
dc.identifier.citedreference | Brown VA, Patel KR, Viskaduraki M, et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin‐like growth factor axis. Cancer Res. 2010; 70: 9003 – 9011. | en_US |
dc.identifier.citedreference | Xie J, Itzkowitz SH. Cancer in inflammatory bowel disease. World J Gastroenterol. 2008; 14: 378 – 389. | en_US |
dc.identifier.citedreference | Marier J‐F, Vachon P, Gritsas A, et al. Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked‐rat model. J Pharmacol Exp Ther. 2002; 302: 369 – 373. | en_US |
dc.identifier.citedreference | Yu C, Shin YG, Chow A, et al. Human, rat, and mouse metabolism of resveratrol. Pharm Res. 2002; 19: 1907 – 1914. | en_US |
dc.identifier.citedreference | Boocock DJ, Faust GES, Patel KR, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev. 2007; 16: 1246 – 1252. | en_US |
dc.identifier.citedreference | Almeida L, Vaz‐da‐Silva M, Falcão A, et al. Pharmacokinetic and safety profile of trans‐resveratrol in a rising multiple‐dose study in healthy volunteers. Mol Nutr Food Res. 2009; 53: S7 – S15. | en_US |
dc.identifier.citedreference | Calamini B, Ratia K, Malkowski MG, et al. Pleiotropic mechanisms facilitated by resveratrol and its metabolites. Biochem J. 2010; 429: 273 – 282. | en_US |
dc.identifier.citedreference | Hoshino J, Park E‐J, Kondratyuk TP, et al. Selective synthesis and biological evaluation of sulfate‐conjugated resveratrol metabolites. J Med Chem. 2010; 53: 5033 – 5043. | en_US |
dc.identifier.citedreference | De Santi C, Pietrabissa A, Mosca F, et al. Glucuronidation of resveratrol, a natural product present in grape and wine, in the human liver. Xenobiotica. 2000; 30: 1047 – 1054. | en_US |
dc.identifier.citedreference | Das S, Lin H‐S, Ho PC, et al. The impact of aqueous solubility and dose on the pharmacokinetic profiles of resveratrol. Pharm Res. 2008; 25: 2593 – 2600. | en_US |
dc.identifier.citedreference | Larrosa M, Tomé‐Carneiro J, Yáñez‐Gascón MJ, et al. Preventive oral treatment with resveratrol pro‐prodrugs drastically reduce colon inflammation in rodents. J Med Chem. 2010; 53: 7365 – 7376. | en_US |
dc.identifier.citedreference | Reagan‐Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2007; 22: 659 – 661. | en_US |
dc.identifier.citedreference | Goswami SK, Das DK. Resveratrol and chemoprevention. Cancer Lett. 2009; 284: 1 – 6. | en_US |
dc.identifier.citedreference | Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997; 275: 218 – 220. | en_US |
dc.identifier.citedreference | Sgambato A, Ardito R, Faraglia B, et al. Resveratrol, a natural phenolic compound, inhibits cell proliferation and prevents oxidative DNA damage. Mutat Res. 2001; 496: 171 – 180. | en_US |
dc.identifier.citedreference | Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006; 5: 493 – 506. | en_US |
dc.identifier.citedreference | de la Lastra CA, Villegas I. Resveratrol as an anti‐inflammatory and anti‐aging agent: Mechanisms and clinical implications. Mol Nutr Food Res. 2005; 49: 405 – 430. | en_US |
dc.identifier.citedreference | Li ZG, Hong T, Shimada Y, et al. Suppression of N‐nitrosomethylbenzylamine (NMBA)‐induced esophageal tumorigenesis in F344 rats by resveratrol. Carcinogenesis. 2002; 23: 1531 – 1536. | en_US |
dc.identifier.citedreference | Sengottuvelan M, Viswanathan P, Nalini N. Chemopreventive effect of trans‐resveratrol — a phytoalexin — against colonic aberrant crypt foci and cell proliferation in 1,2‐dimehtylhydrazine induced colon carcinogenesis. Carcinogenesis. 2006; 27: 1038 – 1046. | en_US |
dc.identifier.citedreference | Tessitore L, Davit A, Sarotto I, et al. Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21CIP expression. Carcinogenesis. 2000; 21: 1619 – 1622. | en_US |
dc.identifier.citedreference | Banerejee S, Bueso‐Ramos C, Aggarwal BB. Suppression of 7,12‐dimethylbenz(a)anthracene‐induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor‐κB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res. 2002; 62: 4945 – 4954. | en_US |
dc.identifier.citedreference | Wood LG, Wark PAB, Garg ML. Antioxidant and anti‐inflammatory effects of resveratrol in airway disease. Antioxid Redox Signal. 2010; 13: 1535 – 1548. | en_US |
dc.identifier.citedreference | Losso JN, Truax RE, Richard G. trans ‐Resveratrol inhibits hyperglycemia‐induced inflammation and connexin downregulation in retinal pigment epithelial cells. J Agric Food Chem. 2010; 58: 8246 – 8252. | en_US |
dc.identifier.citedreference | Larrosa M, Yañéz‐Gascón MJ, Selma MV, et al. Effect of a low dose of dietary resveratrol on colon microbiota, inflammation and tissue damage in a DSS‐induced colitis rat model. J Agric Food Chem. 2009; 57: 2211 – 2220. | en_US |
dc.identifier.citedreference | Cui X, Jin Y, Hofseth AB, et al. Resveratrol suppresses colitis and colon cancer associated with colitis. Cancer Prev Res. 2010; 3: 549 – 559. | en_US |
dc.identifier.citedreference | Youn J, Lee J‐S, Na H‐K, et al. Resveratrol and piceatannol inhibit iNOS expression and NF‐κB activation in dextran sulfate sodium‐induced mouse colitis. Nutr Cancer. 2009; 61: 847 – 854. | en_US |
dc.identifier.citedreference | Singh UP, Singh NP, Singh B, et al. Resveratrol (trans‐3,5,4′‐trihydroxystilbene) induces silent mating type information regulation‐1 and down‐regulates nuclear transcription factor‐κB activation to abrogate dextran sulfate sodium‐induced colitis. J Pharmacol Exp Ther. 2010; 332: 829 – 839. | en_US |
dc.identifier.citedreference | Sánchez‐Fidalgo S, Cárdeno A, Villegas I, et al. Dietary supplementation of resveratrol attenuates chronic colonic inflammation in mice. Eur J Pharmacol. 2010; 633: 78 – 84. | en_US |
dc.identifier.citedreference | Martín AR, Villegas I, Sánchez‐Hidalgo M, et al. The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. Br J Pharmacol. 2006; 147: 873 – 885. | en_US |
dc.identifier.citedreference | Uguralp S, Irsi C, Aksoy T, et al. Resveratrol attenuates inflammation and stricture formation in experimental caustic esophageal burns. Pediatr Surg Int. 2008; 24: 425 – 430. | en_US |
dc.identifier.citedreference | Chavez E, Reyes‐Gordillo K, Segovia J, et al. Resveratrol prevents fibrosis, NF‐κB activation and TGF‐β increases induced by chronic CCL4 treatment in rats. J Appl Toxicol. 2008; 28: 35 – 43. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.